Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up (Q59273856)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25096609%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

title

Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25096609%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

0 references

1 reference

ESMO Guidelines Working Group

7

object named as

ESMO Guidelines Working Group

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25096609%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

author name string

J Bellmunt

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25096609%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

A Orsola

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25096609%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

J J Leow

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25096609%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

T Wiegel

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25096609%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

M De Santis

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25096609%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

A Horwich

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25096609%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

publication date

5 August 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25096609%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25096609%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

volume

25 Suppl 3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25096609%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

issue

suppl 3

0 references

page(s)

iii40-8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25096609%20AND%20SRC:MED&resulttype=core&format=json

The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee

12 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU223

ICUD-EAU International Consultation on Bladder Cancer 2012: Pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU223

EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU223

EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU223

ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU223

Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU223

Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU223

Radiotherapy With Concurrent Carbogen and Nicotinamide in Bladder Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU223

Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU223

Trimodality treatment and selective organ preservation for bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU223

Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates--the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU223

Radiotherapy for bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU223

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU223

Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU223

Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU223

Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU223

Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU223

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU223

Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU223

Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU223

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU223

ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU223

Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU223

Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU223

Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU223

Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU223

Functional copy-number alterations in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU223

Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU223

Frequent truncating mutations of STAG2 in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU223

Genome sequencing identifies a basis for everolimus sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU223

Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU223

Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU223

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDU223

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25096609%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference